177 related articles for article (PubMed ID: 38594748)
1. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Role of p60AmotL2 in Epithelial Extrusion and Cell Detachment.
Cui W; Subramani A; Fonseca P; Zhang Y; Tong L; Zhang Y; Egevad L; Lundqvist A; Holmgren L
Cells; 2023 Aug; 12(17):. PubMed ID: 37681890
[TBL] [Abstract][Full Text] [Related]
3. Modulation of E-Cadherin Function through the AmotL2 Isoforms Promotes Ameboid Cell Invasion.
Subramani A; Cui W; Zhang Y; Friman T; Zhao Z; Huang W; Fonseca P; Lui WO; Narayanan V; Bobrowska J; Lekka M; Yan J; Conway DE; Holmgren L
Cells; 2023 Jun; 12(13):. PubMed ID: 37443716
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
5. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer.
Druzhyna N; Szczesny B; Olah G; Módis K; Asimakopoulou A; Pavlidou A; Szoleczky P; Gerö D; Yanagi K; Törö G; López-García I; Myrianthopoulos V; Mikros E; Zatarain JR; Chao C; Papapetropoulos A; Hellmich MR; Szabo C
Pharmacol Res; 2016 Nov; 113(Pt A):18-37. PubMed ID: 27521834
[TBL] [Abstract][Full Text] [Related]
6. Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
Hansen MB; Postol M; Tvingsholm S; Nielsen IØ; Dietrich TN; Puustinen P; Maeda K; Dinant C; Strauss R; Egan D; Jäättelä M; Kallunki T
Cell Oncol (Dordr); 2021 Aug; 44(4):805-820. PubMed ID: 33939112
[TBL] [Abstract][Full Text] [Related]
7. BET inhibitor suppresses melanoma progression
Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
[No Abstract] [Full Text] [Related]
8. [Identification of a new pro-invasion factor in tumor microenvironment: progress in function and mechanism of extracellular ATP].
Fang WG; Tian XX
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):188-195. PubMed ID: 28416823
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
10. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.
Mertens S; Huismans MA; Verissimo CS; Ponsioen B; Overmeer R; Proost N; van Tellingen O; van de Ven M; Begthel H; Boj SF; Clevers H; Roodhart JML; Bos JL; Snippert HJG
Cell Rep; 2023 Apr; 42(4):112324. PubMed ID: 37000626
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
12. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
13. Dehydropeptidase 1 promotes metastasis through regulation of E-cadherin expression in colon cancer.
Park SY; Lee SJ; Cho HJ; Kim TW; Kim JT; Kim JW; Lee CH; Kim BY; Yeom YI; Lim JS; Lee Y; Lee HG
Oncotarget; 2016 Feb; 7(8):9501-12. PubMed ID: 26824987
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
[TBL] [Abstract][Full Text] [Related]
15. Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression.
Paschall AV; Zimmerman MA; Torres CM; Yang D; Chen MR; Li X; Bieberich E; Bai A; Bielawski J; Bielawska A; Liu K
BMC Cancer; 2014 Jan; 14():24. PubMed ID: 24422988
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain is a novel regulator of TAZ and its activity.
Duan Q; Xiao Y; Zhu L; Liu Z; Mao X; Zhou Z; Liao C; Cai J; Huang F; Liu Z; Zeng J; Xia K; Chang C; Qi J; Chen Z; Huang H; Yang T
Biochim Biophys Acta; 2016 Dec; 1859(12):1527-1537. PubMed ID: 27717711
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
[TBL] [Abstract][Full Text] [Related]
18. lincRNA-p21 Mediates the Anti-Cancer Effect of Ginkgo Biloba Extract EGb 761 by Stabilizing E-Cadherin Protein in Colon Cancer.
Chang L; Liu T; Chai Z; Jie S; Li Z; Liu M; Dong W; Wang X; Zhou B
Med Sci Monit; 2018 Dec; 24():9488-9496. PubMed ID: 30594943
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
20. Lymphatic Invasion of Plakoglobin-Dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer.
Küçükköse E; Laoukili J; Gorelick AN; Degner S; Laclé MM; van den Bent L; Peters NA; Verheem A; Hung WT; Frenkel NC; Wassenaar ECE; Lansu N; Lenos KJ; Vermeulen L; Koopman M; Roodhart JML; Kops GJPL; Borel Rinkes IHM; Hagendoorn J; Naxerova K; Kranenburg O
Gastroenterology; 2023 Aug; 165(2):429-444.e15. PubMed ID: 36906044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
